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Anemia and red blood cell (RBC) transfusion occur frequently in hospitalized patients with cardiac disease. In this
narrative review, we report the epidemiology of anemia and RBC transfusion in hospitalized adults and children
(excluding premature neonates) with cardiac disease, and on the outcome of anemic and transfused cardiac
patients. Both anemia and RBC transfusion are common in cardiac patients, and both are associated with mortality.
RBC transfusion is the only way to rapidly treat severe anemia, but is not completely safe. In addition to hemoglobin
(Hb) concentration, the determinant(s) that should drive a practitioner to prescribe a RBC transfusion to cardiac
patients are currently unclear. In stable acyanotic cardiac patients, Hb level above 70 g/L in children and above 70 to
80 g/L in adults appears safe. In cyanotic children, Hb level above 90 g/L appears safe. The appropriate threshold
Hb level for unstable cardiac patients and for children younger than 28 days is unknown. The optimal transfusion
strategy in cardiac patients is not well characterized. The threshold at which the risk of anemia outweighs the risk of
transfusion is not known. More studies are needed to determine when RBC transfusion is indicated in hospitalized
patients with cardiac disease.
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Introduction
Red blood cell (RBC) transfusion is common in critically
ill adults and children [1-3]. Patients with cardiac disease
are transfused at higher hemoglobin (Hb) thresholds
than those with non-cardiac illness [1-3]. Both anemia
and RBC transfusion are associated with increased mortal-
ity in cardiac patients. The risk/benefit balance of RBC
transfusion in critically ill cardiac patients is currently a
matter of debate.
This narrative review critically appraises the available
data on the relationship between anemia, RBC transfu-
sion and outcome of critically ill adults and children
with cardiac disease. We discuss the prevalence and risks
of anemia in the ICU, the rationale for RBC transfusion,
the evidence supporting restrictive transfusion strategies,
and the growing interest in goal-directed transfusion
therapy. Premature infants and intraoperative transfusions
will not be addressed in this paper, nor will a detailed* Correspondence: j_lacroix@videotron.ca
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reproduction in any medium, provided the origdiscussion of the relationship between length of storage of
RBC units and outcomes, since the latter is discussed in
other papers [4-7].
Anemia
The prevalence of anemia in adults with heart failure ranges
from 18 to 38% [8]; it was 19.1% in 27 observational studies
indexed before July 2011 that enrolled 233,144 patients
with acute coronary syndrome [9]. Anemia may result in
insufficient oxygen delivery (DO2) to vital organs and tis-
sues if DO2 drops below a critical DO2 (Figure 1). DO2 is
determined by cardiac output (Q’) and arterial content in:
DO2 =Q’ × CaO2
and CaO2 = {(Hb × SaO2 × 1.39) + (PaO2 × 0.0031)} [10]
Any drop of the Hb level decreases CaO2 and DO2 if the
compensatory increase of Q’ is not high enough. Anemia
may be poorly tolerated by patients with cardiac failure
and/or coronary disease because their ability to increase
cardiac output to compensate for anemia is limited [11,12].nger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 Critical oxygen delivery (DO2), cardiac failure, anemia
and multiple organ dysfunction syndrome (MODS). X axis:
systemic DO2; Y axis: global oxygen consumption (VO2). Critical
DO2: level below which DO2 does not meet oxygen demand (O2
supply dependency). (1) In healthy subjects (dotted black and white
line), as DO2 decreases, VO2 remains constant by compensatory
mechanisms (increased cardiac output and cellular O2 extraction).
(2) Cardiac failure limits compensatory increase in cardiac output
(hatched blueline). (3) This limitation is worst in patients with
anemia and heart failure (plain red line) because low hemoglobin
decreases arterial oxygen content (CaO2). (4) Severe cardiac
dysfunction may be associated with systemic inflammatory response
syndrome (SIRS) and multiple organ dysfunction syndrome (MODS),
both of which increase systemic VO2 and therefore critical DO2
(double black line).
Figure 2 Cost-benefit analysis of red blood cell (RBC)
transfusion. The background histogram is drawn from data
published by Carson et al. [13] (with permission) illustrating the
relationship between pre-operative anemia and surgical mortality in
1,958 Jehovah’s Witness patients. Dark blue bars: preoperative
hemoglobin (Hb) versus odds ratio (OR) of death in cardiac patients
(risk of death increases as Hb level falls). Light blue bars: pre-Hb
versus OR of death in patients who were healthy before surgery.
We draw on this histogram: (1) dotted horizontal red line: no risk of
mortality attributable to RBC transfusion (OR = 1); (2) hatched
horizontal red line: hypothetical higher risk of mortality attributable
to RBC transfusion (OR = 5); (3) plain curved black line: pre-operative
Hb versus odds ratio (OR) of death in cardiac patients. A RBC
transfusion is probably more useful than harmful when Hb level is
below the intersection between the black curve describing the risk
of mortality associated with anemia and the red line describing the
risk of mortality attributable to RBC transfusion. If RBC transfusions
are perfectly safe (OR = 1), the dotted horizontal red line and the
black curve cross together at a Hb level of about 110 g/L (black
arrow). If the risk of mortality attributable to RBC transfusion is high
(for example, OR = 5), the hatched horizontal red line and the black
curve cross together at a Hb level of about 80 g/L (red arrow).
Where the true curve lies for cardiac patients is unknown. The
curved line would probably move to the right in severely ill cardiac
patients, and to the left if cardiac dysfunction is milder. The actual
risk of death attributable to RBC transfusions in different cardiac
populations remains to be determined.
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and surgical mortality in 1,958 Jehovah’s Witness patients
with cardiovascular disease who refused transfusion; the
risk of mortality was inversely related to Hb level (Figure 2).
Table 1 summarizes the results of two meta-analyses [9,14]
and six observational studies [15-20] on the relationship in
cardiac adults between anemia and adverse outcomes; a
statistically significant association is reported in almost each
instance. However, it must be underlined that the relation-
ship between anemia and outcome is fundamentally con-
founded in all these studies by co-morbidities that might
have caused the anemia (renal failure, gastro-intestinal
bleeding, iron deficiency, and so on).
A number of host characteristics specific to children,
like growth, fetal Hb, different cardiac diseases and
physiology, may impair their adaptive mechanisms to
anemia. There are few data on the relationship between
anemia and outcomes in cardiac children. Kammache
et al. [21] reported some anemia (Hb < 100 g/L) in 24%
of 218 children with idiopathic dilated cardiomyopathy;
mortality was more frequent in anemic children.Transfusion
In the United States, 7.8% to 92.8% of adults undergoing
cardiac surgery are transfused [22-24]. A transfusion isgiven after cardiac surgery in 38% to 74% of children
[3,25-28].
RBC transfusions are sometimes given to cardiac
patients to rapidly replace blood volume in cases of
postoperative blood losses [29]. In the absence of ac-
tive bleeding, some practitioners declare that low Hb
concentration and/or signs of inadequate DO2 (low
central venous O2 saturation (ScvO2), high lactate
level, low SaO2/FiO2 ratio) would prompt them to
prescribe RBC transfusions in this population [29].
There is no doubt that Hb level is a very important
determinant of RBC transfusions in critically ill pa-
tients [30-32]. However, there are data suggesting
that Hb level is not the only determinant of RBC
transfusions in cardiac patients. In a retrospective
study on transfusions in pediatric cardiac ICU [24],
admission Hb ranged from 141 to 150 g/L, nadir
Hb level was 121 g/L in patients who were not
Table 1 Anemia and outcomes in cardiac adults: observations studies
Health problem Patients Studies Risk
Outcome (n) (n) (95% CI)
Meta-analyses
Mortalitya [14] ACS 51,449 10 aOR: 1.49 (1.24 to 1.79)
Mortalityb [9] ACS 171,915 27 aHR: 1.49 (1.23 to 1.81)
Studies not included in the meta-analyses
Mortality [15] New heart failure 12,065 1 aHR: 1.34 (1.24 to 1.46)
Mortality [16] PCI 6,116 1 aHR: 1.8 (1.3 to 2.3)
Mortality [17] PCI 48,851 1 aOR: 2.29 (1.79 to 2.92)
Mortality [18] Cardiac surgery 13,843 1 12.5% versus 7.5%, P = 0.014
Mortality [19] CABG 2,102 1 aOR: 0.99 (0.98 to 1.0)
Mortality [20] ACS 7,922 1 aOR: 1.71 (1.34 to 2.17)
Meta-analyses on other outcomes
Heart failurea [14] ACS 152,849 5 OR: 1.96 (1.47 to 2.62)
Cardiogenic shocka [14] ACS 129,136 4 OR: 1.95 (1.04 to 2.64)
Reinfarctionb [9] ACS 22,115 6 RR: 1.25 (1.02 to 1.53)
ACS: acute coronary syndrome; aHR: adjusted HR; aOR: adjusted odds ratio; CABG: coronary artery bypass graft; CI: confidence interval; HR: hazard ratio; OR: odds
ratio; PCI: percutaneous coronary intervention; RR: relative risk.
This table reports data from two meta-analyses [9,14] and six observational studies [15-20] that were not included in these meta-analyses.
aOverall, the meta analysis conducted by Liu et al. [14] included 241,293 patients enrolled in 19 studies; the analysis on mortality (10 studies) disclosed a very
important heterogeneity (I2 = 84%).
bOverall, the meta analysis conducted by Lawler et al. [9] included 233,144 patients. The analyses on mortality and reinfarction included 27 and 10 studies
respectively; an important heterogeneity was found in both instances (I2 = 98.2% and 48.4% respectively).
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115 g/L in a high transfusion group, suggesting that
transfusions may have been given for reasons other
than anemia. Age below one year, low weight, high
severity of illness as measured by the acute physi-
ology and chronic health evaluation (APACHE) or
pediatric risk of mortality (PRISM) score, cardiopul-
monary bypass, cyanotic heart condition and lower
admission Hb level are also reported to be independ-
ently associated with increased administration of
RBC transfusions [24,33].
Risks and benefits of RBC transfusions
Non-cardiac patients
RBC transfusion should be given only when the risk/bene-
fit ratio is favorable (ratio < 1). The threshold at which the
risks of anemia outweigh the risks of transfusion is cur-
rently unknown.
There are little available hard data on the clinical ben-
efits of RBC transfusion. In a prospective study that
enrolled 303 Kenyan children with Hb below 50 g/L at
hospitalization, 116 (38%) did not receive a transfusion,
mostly because of blood unavailability, while 187 did;
the mortality was significantly higher in non-transfused
children (41.4% versus 21.4%, P < 0.001) [34]. This study
suggests that RBC transfusion may improve the survival of
anemic hospitalized patients with Hb level below 50 g/L,
but what threshold above 50 g/L should be used toprescribe a RBC transfusion in cardiac patients remains a
matter of debate.
Adult cardiac patients
The available evidence suggests that RBC transfusion in
patients with cardiac disease is an independent risk fac-
tor of mortality (Table 2).
Three studies reported some transfusion benefits if the
Hb level is low (<80 g/L), but they also reported harm
with high Hb level [35,36,46]. A retrospective descriptive
epidemiological study of 78,974 patients older than 65
years with acute myocardial infarction showed that RBC
transfusion was associated with a lower risk of 30-day
mortality if hematocrit was below 24% (odds ratio (OR):
0.22; 95% CI: 0.11 to 0.45) or between 30% and 33%
(OR: 0.69; 95% CI: 0.53 to 0.89), but not in cardiac pa-
tients with hematocrit above 33% [46]. Alexander et al.
[35] reported that RBC transfusion tended to have a
beneficial impact on mortality if the nadir hematocrit
was ≤ 24% (adjusted odds ratio (aOR): 0.68; 95% CI: 0.45
to 1.02), but the opposite was found if it was > 30%
(aOR: 3.47; 95% CI: 2.30 to 5.23). Aronson et al. [36] re-
ported that RBC transfusion in patients with myocardial
infarction decreased the risk of mortality if the pre-
transfusion Hb level was ≤ 80 g/L (adjusted hazard ratio
(aHR): 0.13: 95% CI: 0.03 to 0.65), but the risk was in-
creased if the Hb level was > 80 g/L (aHR: 2.2; 95%
CI: 1.5 to 3.3). Shehata et al. [19] reported a lower risk
Table 2 Red blood cell (RBC) transfusions and outcomes in cardiac patients: observational studiesa
Health problem Patients Riskc
Outcome, first author, yearb (n) (95% CI) P-value
Outcome: mortality in adults
Mortality, Alexander, 2008 [35] ACS 44,242 OR: 3.2 (2.9 to 3.6)
ACS and Hct≤ 24% aOR: 0.68 (0.45 to 1.02)
ACS and Hct = 24 to 27% aOR: 1.01 (0.79 to 1.30)
ACS and Hct = 27 to 30% aOR: 1.18 (0.92 to 1.50)
ACS and Hct > 30% aOR: 3.47 (2.30 to 5.23)
Mortality, Aronson, 2008 [36] AMI 2,358 aHR: 0.13 (0.03 to 0.65)d,e 0.013
aHR: 2.2 (1.5 to 3.3)d,f < 0.0001
Mortality, Jani, 2007 [37] AMI 4,623 aOR: 2.02 (1.47 to 2.79) < 0.0001
RR: 4.83 (3.81 to 6.12)d
Mortality, Jolicœur, 2009 [38] AMI 5,188 RR: 6.38 (4.88 to 8.34)
5,532 aHR: 2.16 (1.20 to 3.88) < 0.0001
5,188 RR: 6.38 (4.88 to 8.34)d
Mortality, Koch, 2006 [39] CABG 5,814 OR: 1.77 (1.67 to 1.87) < 0.0001
Mortality, Murphy, 2007 [40] Cardiac surgery (UK) 8,518 HR: 6.69 (3.66 to 15.1) < 0.05
Mortality, Nikolsky, 2009 [41] AMI 2,060 HR: 4.71 (1.97 to 11.36)
RR: 2.92 (1.62 to 5.24)d
Mortality, Pattakos, 2012 [42] Cardiac surgery 644 95% versus 89% 0.007
Mortality, Rao, 2004 [43] ACS 24,112 aHR: 3.94 (3.26 to 4.75) < 0.05
RR: 2.60 (2.22 to 3.03)d < 0.05
Mortality, Shehata, 2012 [19] CABG 2,102 OR: 0.44 (0.32 to 14.1) NS
Mortality, Shishehbor, 2009 [44] AMI 3,575 aHR: 3.89 (2.66 to 5.68) < 0.001
RR: 1.30 (0.90 to 1.88)d < 0.001
Mortality, Singla, 2007 [45] AMI 370 RR: 2.36 (1.49 to 3.76)d
Mortality, Wu, 2001, [46] AMI 78,974 RR: 2.51 (2.42 to 2.61)d,g < 0.05
Mortality, Yang, 2005 [47] AMI 85,111 aOR: 1.67 (1.48 to 1.88) < 0.05
RR: 3.03 (2.85 to 3.21)d < 0.05
Outcomes: myocardial infarction or
ischemic eventsh in adults
AMI, Jani, 2007 [37] AMI 4,623 RR: 1.19 (0.82 to 1.74)d
AMI, Jolicœur, 2009 [38] AMI 5,188 RR: 3.05 (1.85 to 5.04)d
IEh, Murphy, 2007 [40] Cardiac surgery (UK) 8,518 aOR: 3.35 (2.68 to 4.35)c < 0.05
AMI, Nikolsky, 2009 [41] AMI 2,060 RR: 3.28 (1.44 to 7.49)d
AMI, Pattakos, 2012 [42] Cardiac surgery 644 2.8% versus 0.31% < 0.01
AMI + death, Rao, 2004 [43] ACS 2,401 HR: 3.08 (2.84 to 3.35)d < 0.05
AMI, Shishehbor, 2009 [44] ACS 3,575 aHR : 3.44 < 0.001
AMI + death, Singla, 2007 [45] AMI 370 aOR: 2.57 (1.41 to 4.69) < 0.001
RR: 2.10 (0.83 to 5.30)d
AMI, Yang, 2005 [47] AMI 85,111 aOR: 0.95 (0.83 to 1.09)d < 0.05
Outcomes in children Health problem Children Riskc P-value
LMV (days), 2011 [48] Cardiac surgery 270 HR: 0.71 (0.54 to 0.92) 0.009
LMV (days), 2013 [49] Cardiac surgery 335 HR: 2.6 (2.0 to 3.4) < 0.001
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Table 2 Red blood cell (RBC) transfusions and outcomes in cardiac patients: observational studiesa (Continued)
PICU LOS (days), 2013 [49] Cardiac surgery 335 LOS: 8 ± 0.9 versus 3.5 ± 2 < 0.001
Hospital LOS, 2011 [24] Cardiac surgery 802 aHR: 0.65 (0.49 to 0.87) < 0.001
Wound infection, 2010 [50] Cardiac surgery 216 aOR: 7.87 (1.63 to 37.92) < 0.001
ACS: acute coronary syndrome; aHR: adjusted HR; AMI: acute myocardial infarction; aOR: adjusted OR; CABG: coronary artery bypass graft; card surg: cardiac
surgery; CI: confidence interval; Hct: hematocrit; HR: hazard ratio; IE: ischemic events; LMV: length of MV; LOS: length of stay; MI: myocardial infarction; MV:
mechanical ventilation; OR: odds ratio; PICU: pediatric intensive care unit; RBC: red blood cell; NS: not significant; RCT: randomized controlled trial; UK:
United Kingdom.
aStudies on the relationship between the length of storage of RBC units and outcomes of transfused cardiac patients are excluded from this table.
bYear of publication.
cTransfused patients versus no RBC transfusion or restricted RBC transfusion strategy.
dChatterjee et al. [51] completed a systematic review that included the studies marked byd in this table, plus a small RCT conducted by Cooper et al. [52]. Overall,
the risk ratio of death in transfused patients versus controls was 2.91 (95% confidence interval (CI): 2.46 to 3.44), but there was a very significant
heterogeneity (I2 = 92%).
ePre-transfusion hemoglobin concentration ≤ 80 g/L.
fPre-transfusion hemoglobin concentration > 80 g/L.
gThe study by Wu et al. [46] enrolled patients ≥ 65 years of age with AMI. RBC transfusion was associated with a reduction in 30-day mortality if hematocrit < 24%
(aOR = 0.22; 95% CI: 0.11 to 0.45) or between 30% and 33% (aOR = 0.69; 95% CI: 0.53 to 0.89), but the risk of mortality was not increased in patients with a
hematocrit > 33% who received RBC transfusion.
hIschemic events: myocardial infarction, stroke, renal impairment, or failure.
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onary artery bypass graft (CABG), but the association was
not statistically significant (adjusted OR (aOR) = 0.44; 95%
CI: 0.32 to 14.1).
On the other hand, six studies of adults undergoing
cardiac surgery, CABG or with myocardial infarction re-
ported increased mortality in transfused cardiac patients
[39,40,42-44,47]. Rao et al. [43] published a descriptive
epidemiological study on 24,112 patients with acute cor-
onary syndrome who were enrolled in three large ran-
domized controlled trials (RCTs). They compared the
outcomes of those who received at least one RBC trans-
fusion (n = 21,711) and those who did not (n = 2,401);
RBC transfusion was associated with an increased HR
for 30-day mortality (HR = 3.94; 95% CI: 3.26 to 4.75).
Probability of 30-day mortality was higher in transfused
patients with nadir hematocrit values above 25%. In the
systematic review of Chatterjee et al. [51], the risk ratio
of death in transfused patients versus controls was 2.91
(95% CI: 2.46 to 3.44) and the risk of secondary myocar-
dial infarction was 2.04 (95% CI: 1.06 to 3.93), but there
was a very significant heterogeneity in both instances
(I2: 92% and 98% respectively). Garfinkle et al. [53] also
published a systematic review on 11 observational stud-
ies that enrolled 290,847 patients with acute coronary
syndrome: the unadjusted OR of mortality in transfused
patients ranged from 1.9 to 11.2; a meta-analysis was
not performed because there was too much heterogen-
eity, but the data suggested a protective effect of RBC
transfusion if nadir Hb drops below 80 g/L and neutral
or harmful effects above 110 g/L. In summary, there is
evidence in adults with cardiac disease that RBC trans-
fusion is associated with mortality and ischemic events.
Pediatric cardiac patients
There is less evidence in children. Three studies reported
prolonged length of mechanical ventilation in children whoreceived RBC transfusion after cardiac surgery [48,49,54],
three reported prolonged length of PICU and/or hospital
stay [24,49,54] and three reported an increased incidence of
infections [33,50,54]. In 657 consecutive children undergo-
ing open heart surgery, Székely et al. [33] found an associ-
ation between total volume of blood transfusion and the
rate of infections (aOR: 1.01; 95% CI: 1.002 to 1.02,
P < 0.01), but no association with mortality (aOR: 1.00;
95% CI: 0.99 to 1.02, P = 0.65).
Risks/benefits of RBC transfusions: summary
Is it justified to prescribe more RBC transfusions to car-
diac than to non-cardiac ICU patients? The available data
on this question are inconclusive: while some descriptive
studies suggest a benefit to transfusion, most studies asso-
ciate RBC transfusion to worse outcomes. Descriptive
studies cannot prove that there is a cause-effect relation-
ship between a risk factor and a given outcome: adjust-
ment for confounders like volume of RBC transfusion and
administration of other blood products can be done, but a
possibility always remains that unknown confounders play
a role. Moreover, severity of illness is associated with both
transfusion and mortality [8,24]. A multivariate analysis
cannot deconstruct such confounding by indication [55];
only RCTs can [56].
Transfusion related adverse events
The safety of blood products with respect to transfusion-
transmitted infectious diseases has improved greatly in
recent decades. Presently, the greatest concern is non-
infectious serious hazards of transfusion (NISHOT) [57-59].
NISHOT may be non-immune or immune-mediated.
Short-term non-immune NISHOT include transfusion-
related circulatory overload (TACO) and overtransfu-
sion. Overtransfusion is of concern because of the risk
of TACO and/or hyperviscosity. Viscous blood flow
may impair DO2 in small vessels and decrease coronary
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transfused patients: 19% of them were overtransfused
according to the British RBC transfusion guidelines.
Sabatine et al. [61] reported an increased mortality in
patients with ST-elevation myocardial infarction when
Hb value was > 170 g/L (OR = 1.79; 95% CI: 1.18 to 2.71,
P = 0.007) and > 160 g/L (OR = 1.31; 95% CI: 1.03 to
1.66, P = 0.027) in patients with non-ST-elevation myo-
cardial infarction.
Immune-mediated NISHOT include hemolytic and al-
lergic reactions, transfusion-related immunomodulation
(TRIM), transfusion-related acute lung injury (TRALI),
nosocomial infections, transfusion-associated graft versus
host disease, and alloimmunization to RBC and HLA anti-
gens [57,62,63].
In critically ill cardiac patients, TRIM may represent a
significant ‘second-hit’ when added to pre-existing organ
dysfunction and/or a systemic inflammatory response
syndrome (SIRS), which may result in TRALI and
multiple organ dysfunction syndrome. Vlaar et al. [64]
reported that in cardiac surgery patients, RBC transfu-
sion was associated with an increase pulmonary leak
index, an early marker of acute lung injury. Inflamma-
tory markers in bronchoalveolar lavage were increased
in transfused cardiac surgery patients when compared
to controls [65]. TRALI may be an important under-
diagnosed cause of lung injury in cardiac and non-
cardiac ICU patients [66,67].
Although NISHOT are currently the most important
causes of transfusion-related fatalities, their incidence




Bracey, 1999 [73] CABG
Carson, 2011 [74] Hip surgeryc
Cooper, 2001 [52] Myocardial infarction
Hajjar, 2012 [23] Cardiac surgery
Hébert, 2001 [75] ICU cardiac patients
Johnson, 1992 [76] CABG
Shehata, 2012 [19] Cardiac surgery
Pediatric cardiac surgery
Cholette, 2011 [77] Cyanotic
de Gast-Bakker, 2013 [78] Non-cyanotic
Willems, 2010 [79] Non-cyanotic
ARR: absolute risk reduction; CABG: coronary artery bypass graft; CI: confidence inte
aYear of publication.
bRestrictive versus liberal transfusion strategy.
cHip surgery in patients older than 50 years with atherosclerosis.
dNo significant difference in duration or degree of exercise was demonstrated betwRestrictive or liberal RBC transfusion strategy
As illustrated in Figure 1, the relationship between DO2
and O2 consumption (VO2) remains horizontal as long
as compensatory mechanisms (increasing cardiac output
and O2 extraction) are still effective [10,68]. However,
VO2 drops with DO2 below a critical threshold. Anemia
decreases DO2 and it is unmistakably deleterious below
a certain threshold. The critical Hb level threshold below
which DO2 becomes significantly impaired and transfu-
sion becomes less harmful than persisting anemia is un-
known and likely varies depending upon the underlying
condition and clinical status of each patient. Anemia is
well endured by healthy subjects: acute isovolemic reduc-
tion of Hb level down to 50 g/L was hemodynamically
well tolerated by 11 resting healthy humans [69], but
delayed memory was observed in 31 healthy young volun-
teers after a similar reduction of Hb [70]. However, cardiac
patients may have higher thresholds of critical DO2 than
healthy adults and target Hb for transfusion might be dif-
ferent (Figures 1 and 2). Moreover, patients with cardiac
disease may also be more vulnerable than the general
population to adverse effects of transfusion (disturbed
rheology [71] and coagulation [65], NISHOT [57], dys-
functional vasoregulation [72], circulatory overload, and
so on).
Confronted with the risks of transfusion and a growing
body of literature associating RBC transfusion with ad-
verse outcomes, a number of RCTs have now compared
the safety of adopting a restrictive versus liberal RBC
transfusion strategy (low versus higher threshold Hb) in
critically ill patients with cardiac disease (Table 3).ion strategy in cardiac patients: randomized clinical trials
Patients Mortalityb
(n) (95% CI) P-value
428 RR: 0.52 (0.13 to 2.04) NS
2,016 ARR: 0.9 (−1.5 to +3.4) NS
46 8% versus 5% 1.0
502 6% versus 5% 0.93
357 22.5% versus 22.7% 1.00
38 No differenced NS
50 16% versus 4% NS
60 1 death NS
107 No death NS
125 12.7% versus 6.5% 0.36
rval; RBC: red blood cell; NS: not statistically significant.
een the two groups.
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We found seven RCTs conducted in adults with cardiac
illness [19,23,52,73-76]; all enrolled only hemodynamically
stable patients. All but one [23] reported that a restrictive
strategy was as safe or safer than a liberal strategy. Three
RCTs included more than 50 patients.
In 1999, Hébert et al. [80] published the ‘Transfusion
Requirements in Critical Care’ (TRICC) study. Euvolemic
patients were randomized to receive a RBC transfusion if
Hb level was below 100 g/L (liberal strategy) or below 70
g/L (restrictive strategy). Patients with acute myocardial
infarction and unstable angina were excluded. A subgroup
analysis of 357 patients with cardiovascular disease was
published in 2001 [75]; the 30-day all-cause mortality was
similar (22.5% versus 22.7%, P = 1.00).
Hajjar et al. [23] published a single center non-inferiority
RCT of 502 adults undergoing cardiac surgery who were
allocated to receive a transfusion if hematocrit was below
24% or 30%. The pre-transfusion Hb level was 91 in the re-
strictive and 105 g/L in the liberal group. They found a
similar incidence of 30-day all-cause mortality (6% in the
restrictive and 5% in the liberal group, P = 0.93), cardio-
genic shock (5% versus 9%, P = 0.42), acute respiratory
distress syndrome (1% versus 2%, P = 0.99) and acute
renal failure (5% versus 4%, P = 0.99). The number of
RBC units transfused was independently associated with
30-day all-cause mortality (HR = 1.2/unit; 95% CI: 1.1 to
1.4, P = 0.002).
Carson et al. [74] published the ‘Functional Outcomes
in Cardiovascular Patients Undergoing Surgical Hip Frac-
ture Repair’ (FOCUS) study, a large multicenter RCT of
2,016 adults over 50 years of age with known atheroscler-
otic disease undergoing a hip surgery and who had a Hb
level below 100 g/L within 3 days post-surgery. The re-
strictive group was transfused if Hb level fell below 80 g/L,
the liberal group if below 100 g/L. Primary outcome was
ability to walk 10 feet unassisted or death 60 days post-
randomization. No difference was found in any of the
outcomes, including survival, postoperative complications,
activities of daily living and disposition.
In summary, the available RCTs suggest that a restrict-
ive transfusion strategy (threshold Hb level for transfu-
sion: 70 or 80 g/L) appears as safe as a liberal strategy in
stable adult ICU patients with cardiac disease.
RBC transfusion strategy in cardiac children
Three RCTs compared a restrictive and a liberal transfu-
sion strategy after pediatric cardiac surgery.
In the ‘Transfusion Requirements In PICU’ (TRIPICU)
study [81], 637 stabilized critically ill children were ran-
domized to receive a RBC transfusion if their Hb dropped
below 70 or 95 g/L [81]. Patients were considered stable if
mean systemic arterial pressure was not less than two
standard deviations below the normal mean for age and ifcardiovascular treatment (fluids and/or medication) had
not been increased for at least two hours before enroll-
ment. Children with cyanotic cardiac disease and neonates
under 28 days were excluded. A sub-group analysis of 125
cardiac children enrolled in TRIPICU demonstrated no
significant difference in new or progressive multiple organ
dysfunction syndrome (restrictive versus liberal group:
12.7% versus 6.5%, P = 0.36), PICU length of stay (7.0 ± 5.0
versus 7.4 ± 6.4 days) or 28-day mortality (3.2% versus
3.2%) [79].
An RCT compared the outcome of cardiac children
older than 6 weeks randomized to receive a RBC transfu-
sion if Hb level dropped below 80 g/L or 108 g/L [78].
Patients with cyanotic cardiac disease were excluded.
Randomization occurred before surgery; the research
protocol with respect to RBC transfusion was initiated in
the operating room and maintained up to PICU discharge.
One hundred patients were enrolled and retained for ana-
lysis. Duration of mechanical ventilation, length of PICU
stay and incidence of adverse events were similar in both
groups, but length of hospital stay was shorter in the re-
strictive group (median: 8 {interquartile range: 7 to 11}
versus 9 {7 to 14} days, P = 0.063).
Physicians target higher Hb values for critically ill
children with cyanotic heart disease [28,29]. In an RCT
completed by Cholette et al. [77], 60 children were ran-
domized after Glenn or Fontan palliation to a restrictive
(transfusion if Hb < 90 g/L) or liberal group (<130 g/L).
One death was observed (liberal group). There was no
difference in mean and peak arterial lactate, arterio-
venous and arterio-cerebral oxygen content. Although
not powered to demonstrate statistical significance, mor-
tality, PICU and hospital length of stay, duration of mech-
anical ventilation, dose and duration of inotropic support
were similar.
Goal-directed transfusion therapy
Goal-directed RBC transfusion therapy targeting a physio-
logical goal may be a more appropriate target than specific
Hb levels. The concept of goal-directed therapy is well il-
lustrated by the RCT conducted by Rivers et al. [82]: 266
adults with severe sepsis or septic shock were randomized
to be monitored or not with ScvO2. Patients allocated to
ScvO2 monitoring were also assigned to a bundle of treat-
ment to maintain their ScvO2 over 70%; this bundle in-
cluded, in sequential order, mechanical ventilation, fluid
bolus, vasoactive drugs and RBC transfusion if the
ScvO2 remained under 70% after all other interventions.
Mortality was 30.5% with goal-directed therapy versus
46.5% in controls.
There are currently no hard data on goal-directed trans-
fusion therapy in cardiac patients. Goals that can be con-
sidered include physiologic parameters like DO2 measured
by a Swan-Ganz catheter or locally with near infrared
Du Pont-Thibodeau et al. Annals of Intensive Care 2014, 4:16 Page 8 of 11
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blood lactate, mixed venous O2 saturation (Sv’O2), ScvO2,
tissue O2 saturation and O2 extraction rate [10]. Well-
conducted research is required to demonstrate the reliabil-
ity and clinical applicability of a test before we start to use
it at the bedside. There are examples of tests that were too
rapidly adopted by the medical community. For example,
regional (splanchnic and/or renal) NIRS is frequently used
to detect low cardiac output in ICU patients; a recent
study showed that its positive predictive value is so low
that it cannot be considered a reliable test [83]. Repeated
(‘dynamic’) measurements of NIRS might be more inform-
ative than ‘static’ measures [84], but this remains to be
proven. Transfusion therapy guided by ScvO2 is another
candidate. The results of the trial by Rivers et al. [82] sug-
gested that RBC transfusion might be useful in septic pa-
tients. Another RCT conducted in 102 children with
severe sepsis or fluid refractory shock reported similar
results (mortality: 11.8% versus 39.2% in controls) [85].
However, in the ProCESS three arms RCT [86], 1,341
adults were allocated to a protocol-based goal-directed
therapy that required the placement of a central venous
catheter, a protocol-based standard therapy without
such catheter, or usual care; no difference was observed
in any outcomes, which questions the results of the
RCTs by Rivers and de Oliveira [82,85]. Moreover, the
specific contribution of RBC transfusions was unclear in
these RCTs and none enrolled cardiac patients.
Currently, we do not know what physiologic parameters
we must use to guide a goal-directed transfusion therapy
in cardiac patients. Further clinical studies are required
before a given goal that would help practitioners to pre-
cisely decide when to transfuse cardiac patients can be
recommended in this population.
Conclusion
Anemia is common in patients with cardiac disease and
is associated with mortality and morbidity. RBC transfu-
sion is the best way to rapidly increase the Hb level, but
it is not risk-free: storage lesion and NISHOT, including
prothrombotic and proinflammatory effects, may cause
transfusion-related adverse events.
The Hb level at which the risk of anemia outweighs
the risk of transfusion is not well known. Three observa-
tional studies suggest that there might be some benefit
to give a RBC transfusion to adults with acute coronary
syndrome if their Hb level is < 80 g/L, but many more
studies suggest that RBC transfusion might be harmful
in this population if their Hb level is higher than 80 to
100 g/L. The question of RBC transfusion to adults with
acute coronary syndrome is not addressed in the guide-
lines of the American College of Cardiology, the American
Heart Association and the Canadian Cardiovascular Soci-
ety [87]. However, a number of RCTs in hemodynamicallystable cardiac patients suggest a level of Hb (about 80 g/L)
above which it appears safe not to transfuse, thereby
avoiding the risks related to transfusions.
Data in children are scarce. In stable acyanotic cardiac
children, a Hb level above 70 or 80 g/L appears to be well
tolerated without RBC transfusion. In children with cyan-
otic heart lesions, Hb level over 90 g/L appears safe. The
threshold Hb level for unstable cardiac children and for
neonates is unknown. Goal-directed transfusion therapy is
a promising avenue for future research.
Severity of illness, anemia and transfusions are intercon-
nected with outcome in cardiac patients, and their individ-
ual contribution to outcome remains unresolved. Further
RCTs are necessary to disentangle this relationship.
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